We present the first reported case in the Middle East of bilateral uveal metastasis from prostate cancer in a 74-year-old man. Initially diagnosed in November 2016 with high-volume metastatic castrate-sensitive prostate cancer (mCSPC), his cancer progressed and was castrate-resistant. In December 2022, the patient presented blurry vision in the left eye and was diagnosed with left uveal metastase. Later his disease progressed to the right eye. This case shows the importance of considering ocular metastasis in patients with advanced prostate cancer, highlights the challenges in managing rare metastatic sites, and provides insights into treatment strategies for bilateral uveal metastasis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11345898 | PMC |
| http://dx.doi.org/10.1016/j.eucr.2024.102814 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancer.
World J Urol
December 2024
Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
Purpose: No currently available phase III trial compared docetaxel vs. androgen receptor pathway inhibitors (ARPI) regarding cancer-control outcomes in metastatic hormone-sensitive prostate cancer (mHSPC). Moreover, few is known about the effect of sequential therapies in mHSPC and subsequent metastatic castration resistant prostate cancer (mCRPC).
View Article and Find Full Text PDFShort-Term Urinary Incontinence After Radical Prostatectomy Is Still Based on Patients' Age, Nerve-Sparing Approach, and Surgical-Experience, Despite the Higher-Use of Robotic Surgery in 2022 Compared to 2016 Real-World Results of a Large Rehabilitation Center in Germany.
Cancer Rep (Hoboken)
December 2024
Department of Urology, Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg an der Havel, Germany.
Background: Despite constant improvements, incontinence is one of the most relevant and quality-of-life-reducing side effects of radical prostatectomy (RP) and, in addition to patient-specific factors such as age, the experience of the surgeon/center and the surgical technique used play an important role.
Aims: To present current real-world data on short-term incontinence after RP from one of the largest German rehabilitation centers in 2022 and to compare it to the results from the same institution in 2016.
Methods And Results: Retrospective, unicentric, univariate analysis of data from 1394 men after RP in 2022 on admission and discharge from the rehabilitation clinic.
Filicinic Acid-Based Meroterpenoids with Antiproliferative Activity against Prostate Cancer PC-3 Cells from .
J Org Chem
December 2024
Department of Pharmacy, The First Affiliated Hospital, Jinan University, Guangzhou 510630, China.
Nine new structurally diverse filicinic acid-based meroterpenoids (-) with four kinds of carbon skeletons were isolated from the rhizomes of . Their structures, including the absolute configurations, were elucidated by comprehensive analysis of spectroscopic data, quantum chemical calculations, and single-crystal X-ray diffraction. Structurally, compounds - feature an unprecedented 6/6/5/6/6/6 hexacyclic system with a rare oxaspiro[4.
View Article and Find Full Text PDFCorrection: Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1/STAT4 pathway.
J Exp Clin Cancer Res
December 2024
Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Survival prediction of glioblastoma patients using machine learning and deep learning: a systematic review.
BMC Cancer
December 2024
Department of Data Science, Faculty of Interdisciplinary Science and Technology, Tarbiat Modares University, Tehran, Iran.
Glioblastoma Multiforme (GBM), classified as a grade IV glioma by the World Health Organization (WHO), is a prevalent and notably aggressive form of brain tumor derived from glial cells. It stands as one of the most severe forms of primary brain cancer in humans. The median survival time of GBM patients is only 12-15 months, making it the most lethal type of brain tumor.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!